Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lower Urinary Tract Symptoms (LUTS) Clear all
Recruiting No phase listed Observational

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

NCT05898932
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Medical Management, Surgical Management
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional

Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)

NCT03772808
View directory record Official record
Conditions
BPH, Lower Urinary Tract Symptoms
Interventions
Lycocomfort
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Zenflow Spring System, Sham Procedure
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional Results available

ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

NCT03499964
View directory record Official record
Conditions
Urethral Stricture
Interventions
Optilume Drug Coated Balloon (DCB), Control Treatment
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2006 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

US Imaging for the Assessment of LUTS

NCT06323109
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, BPH
Interventions
MRI-UDS; US-UDS; MCUD
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02930889
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Artery Embolization
Device
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 1Phase 2 Interventional

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

NCT02676544
View directory record Official record
Conditions
Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms
Interventions
Embosphere microspheres
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
50 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed Not applicable Interventional

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

NCT02592473
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), Prostatism, Lower Urinary Tract Symptoms (LUTS), Prostatic Hypertrophy, Hyperplasia, Male Urogenital Diseases, Genital Diseases, Male
Interventions
Embozene Microspheres
Device
Lead sponsor
University of Virginia
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Laguna Hills, California • Long Beach, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional

Reducing Disparities in Urinary Control Symptoms for Minority Women

NCT06798311
View directory record Official record
Conditions
Urinary Incontinence (UI), Lower Urinary Tract Symptoms (LUTS), Pelvic Floor Disorder
Interventions
SUPPORT workbook
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

NCT00410514
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Tuscon, Arizona • Atherton, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia

NCT01387893
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
the Digital Repetitive Infrapubic Pressure maneuver
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

NCT06351683
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Interventions
MitoQ (mitoquinol mesylate), Placebo
Drug · Other
Lead sponsor
Iman Al-Naggar, PhD
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study

NCT04846387
View directory record Official record
Conditions
Healthy
Interventions
Magnetic Resonance Imaging (MRI), Post-Void Residual, Uroflowmetry, Questionaire - AUA Symptom Score
Diagnostic Test · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational

Brain Imaging in Men With Lower Urinary Tract Symptoms

NCT03991429
View directory record Official record
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT01438775
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Huntsville, Alabama • Atherton, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

Tetra-NIRS Clinical Study

NCT00871975
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Urodynamics + TETRA - NIRS
Device
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

NCT01846793
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Results available

Real World Data on Management of Male LUTS

NCT03075449
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 24, 2026, 1:07 AM EDT